Nipah virus has caused repeated, high-fatality outbreaks in India, with Kerala alone experiencing four since 2018 and earlier episodes traced back to West Bengal in 2001. The virus originates in fruit bats, kills a large fraction of those it infects, and has no approved vaccine or treatment available for clinical use. What makes India’s situation particularly concerning is the combination of a wide bat reservoir, dense human populations living alongside those bats, and the possibility of person-to-person spread in hospitals and households.
Where the Virus Comes From
Fruit bats of the genus Pteropus are the natural reservoir for Nipah virus. These bats carry the virus without getting sick themselves, shedding it intermittently through urine, saliva, and droppings.1PLOS Pathogens. The Nipah virus threat in India: Epidemiological trends, risk drivers, and lessons for pandemic preparedness In India, the confirmed bat host is Pteropus medius, a large flying fox found across much of the subcontinent. Surveillance initially focused on insectivorous bat species, but follow-up surveys in Kerala confirmed Pteropus medius as the reservoir, consistent with findings from Bangladesh.2PLOS Neglected Tropical Diseases. Prioritizing surveillance of Nipah virus in India
The virus jumps to people when they come into contact with bat-contaminated food or surfaces. In Bangladesh, the best-documented route is through raw date palm sap. Collectors hang clay pots on palm trees overnight to catch the dripping sap, and bats lick the sap-producing surface, depositing saliva and virus into the pots. A study in Bangladesh found that drinking raw date palm sap was strongly linked to illness, with case-patients roughly eight times more likely to have consumed it than controls.3PubMed Central. Foodborne transmission of Nipah virus, Bangladesh In India, the spillover pathways are less well characterized. Contaminated fruit is suspected, as bats partially eat fruit and drop it, and people or domestic animals may then handle or consume the remains. Kerala’s outbreaks have prompted investigations into whether fruit contamination, well water, or other environmental exposures are the primary route.
India’s Outbreak Timeline
India’s first recognized Nipah outbreak struck Siliguri, West Bengal, in January and February 2001. An unusual cluster of febrile illness with altered consciousness appeared, and laboratory testing confirmed Nipah virus in nine of eighteen patients. Genetic sequencing showed the Siliguri strain was more closely related to Bangladeshi isolates than to the Malaysian strain originally identified in 1998.4PubMed Central. Nipah virus-associated encephalitis outbreak, Siliguri, India A smaller outbreak followed in Nadia, West Bengal, in 2007.
Then the virus appeared in an entirely different part of the country. In May 2018, Kerala’s Kozhikode district reported a cluster of deaths from encephalitis that turned out to be Nipah. That outbreak killed seventeen people, most of them family members or healthcare workers who had close contact with patients. Since then, Kerala has experienced recurrent outbreaks, predominantly in the Kozhikode district, with the most recent occurring in September 2023.5PubMed Central. Recurrent Nipah outbreaks in Kerala: implications for health policy and preparedness The recurrence in a single region highlights gaps in early detection and the persistent risk posed by a bat reservoir that is not going away.
The 2019 Kerala outbreak, by contrast, was contained remarkably well. There was no documented spread beyond the index case and no deaths, a success attributed to aggressive contact tracing, rapid laboratory confirmation, and the institutional knowledge built during the devastating 2018 event.6PubMed Central. Nipah Virus Disease: Recent Perspective and One Health Approach
Symptoms and How the Disease Progresses
Nipah virus infection typically starts with fever, headache, and drowsiness, then progresses rapidly. Patients often develop encephalitis, which shows up as confusion, disorientation, and seizures. Some develop respiratory symptoms, sometimes severe, and the combination of brain inflammation and breathing difficulty is what makes the disease so dangerous.7PubMed Central. Nipah virus disease: A rare and intractable disease Blood tests may show low platelet counts, low white blood cell counts, and elevated liver enzymes.
At the tissue level, the virus attacks blood vessel walls throughout the body, causing widespread inflammation of vessels (vasculitis), blood clotting, and tissue death, especially in the brain. It infects endothelial cells lining the blood vessels and neurons directly, which explains both the severe neurological symptoms and the multi-organ damage seen in fatal cases.8PubMed Central. Nipah virus infection: pathology and pathogenesis of an emerging paramyxoviral zoonosis The virus is both “vasotropic” and “neurotropic,” meaning it has a particular affinity for blood vessels and nerve tissue, and can generate interstitial pneumonia or encephalitis or both.9PubMed. Comparative pathology of the diseases caused by Hendra and Nipah viruses
Case fatality rates have varied by outbreak, ranging from around 40% to over 70% in some Indian and Bangladeshi clusters. The Malaysian outbreak of 1998–1999, where pigs served as an amplifying host, had a lower fatality rate of roughly 40%, while outbreaks driven by the Bangladesh strain tend to be deadlier. The incubation period runs from about four days to two weeks, with most cases developing symptoms within a week of exposure.
Person-to-Person Spread
Unlike many bat-borne viruses, Nipah can spread from one person to another, and this is what makes it especially alarming from a public health standpoint. A fourteen-year investigation of Nipah cases in Bangladesh found that about a third of identified cases resulted from person-to-person transmission, though the overall reproduction number was low, averaging about 0.33, meaning each patient infected fewer than one other person on average.10PubMed Central. Transmission of Nipah Virus – 14 Years of Investigations in Bangladesh That average conceals significant variation: older patients with respiratory difficulty had a much higher transmission potential, approaching a reproduction number just above 1.0, the threshold for sustained spread.
Close physical contact and exposure to body fluids are the key risk factors. Spouses of patients were infected at a far higher rate than other family members or community contacts. The risk climbed steeply with duration of exposure, with those spending more than 48 hours near a patient facing roughly thirteen times the infection risk compared with those exposed for an hour or less.10PubMed Central. Transmission of Nipah Virus – 14 Years of Investigations in Bangladesh In one Bangladeshi community, 92% of confirmed cases had close contact with another sick person before falling ill, and secondary and even tertiary chains of transmission were documented, including between patients sharing hospital beds.11PubMed Central. Person-to-Person Transmission of Nipah Virus in a Bangladeshi Community
Reassuringly, serologic testing of nearly 1,900 asymptomatic contacts in Bangladesh revealed no silent infections, suggesting the virus does not spread easily through casual contact.10PubMed Central. Transmission of Nipah Virus – 14 Years of Investigations in Bangladesh The danger is concentrated around caregiving, whether in homes or hospitals, which is why healthcare workers have been disproportionately affected in Indian outbreaks.
Why the Bangladesh Strain Matters for India
Two major genetic lineages of Nipah virus circulate: the Malaysia strain (NiV-M) and the Bangladesh strain (NiV-B). India’s outbreaks appear linked to the Bangladesh lineage. The Siliguri 2001 virus was more closely related to Bangladeshi isolates than Malaysian ones, and the Kerala outbreaks have similarly been attributed to the Bangladesh clade. This distinction is medically significant. In animal experiments, the Bangladesh strain produced viral RNA levels in oral secretions at least tenfold higher than the Malaysia strain during the same stage of infection, with average cumulative viral shedding more than thirtyfold greater.12PubMed Central. Transmission Routes for Nipah Virus from Malaysia and Bangladesh
Higher viral loads in respiratory and oral secretions likely explain why the Bangladesh strain shows more person-to-person transmission and higher fatality rates than the Malaysian lineage, where human-to-human spread was rarely documented. For India, this means that every outbreak carries an inherent risk of hospital-based or household transmission chains, and containment measures must account for respiratory droplet and body fluid exposure from the outset.
What Happens to Survivors
Surviving Nipah virus does not always mean full recovery. A systematic review and meta-analysis found that about 10% of all infection survivors developed late-onset or relapsing neurological symptoms within one and a half to two years of the initial illness.13The Lancet Regional Health – Southeast Asia. Post-acute sequelae after Nipah virus infection: a systematic review and meta-analysis Among those who developed post-acute problems, two-thirds experienced at least two distinct symptoms, and some reported up to five. These sequelae can appear even after mild or asymptomatic initial infections, which is unsettling because it means the virus may cause hidden damage even when the acute illness seems manageable.14PubMed Central. Post-acute sequelae after Nipah virus infection: a systematic review and meta-analysis
Research in nonhuman primates has offered a possible explanation: the virus can persist in the brain long after the acute infection clears. This viral persistence in the central nervous system may be what triggers the relapsing encephalitis seen in human survivors months or even years later.15PubMed Central. Nipah virus persists in the brains of nonhuman primate survivors The implication for clinical follow-up is clear: people who survive a Nipah outbreak need long-term neurological monitoring, not just a discharge from the ICU.
Diagnosis Is Harder Than It Sounds
Because Nipah virus is classified as a Biosafety Level 4 agent due to its extreme pathogenicity, handling clinical specimens safely requires specialized containment infrastructure, personal protective equipment, and strict protocols.16PubMed Central. Diagnostics for Nipah virus: a zoonotic pathogen endemic to Southeast Asia BSL-4 laboratories are rare in South Asia, and most endemic regions lack them entirely. Workarounds exist: if the virus in the sample can be inactivated right after collection, BSL-3 or even BSL-2 facilities may be sufficient for subsequent testing. But this creates a bottleneck during outbreaks, where rapid diagnosis is the difference between containing a cluster and losing control of it.
After Kerala’s 2018 outbreak, India invested in point-of-care assays and trained healthcare workers in biosafety procedures, which contributed to faster diagnosis and response in subsequent events.17PubMed Central. Experiential learnings from the Nipah virus outbreaks in Kerala towards containment of infectious public health emergencies in India Still, when a case first appears, the symptoms overlap with many common tropical infections, including dengue, Japanese encephalitis, and scrub typhus. Clinical suspicion depends on local awareness, and delays in recognizing the first case in an outbreak cluster remain one of the biggest vulnerabilities.
Treatments Under Development
No antiviral drug is approved specifically for Nipah virus. The most advanced therapeutic candidates are monoclonal antibodies that target the virus’s surface proteins to prevent it from entering cells. A human monoclonal antibody called m102.4 showed dramatic results in African green monkeys: all twelve treated animals survived lethal Nipah challenge, including those treated as late as five days after exposure when clinical signs were already apparent, while untreated controls died within eight to ten days.18PubMed Central. Therapeutic treatment of Nipah virus infection in nonhuman primates with a neutralizing human monoclonal antibody
More recently, a newer antibody called hu1F5 outperformed m102.4 in a head-to-head comparison. In the same nonhuman primate model, all six animals given hu1F5 five days after exposure survived, whereas only one of six treated with m102.4 did.19PubMed. Therapeutic administration of a cross-reactive mAb targeting the fusion glycoprotein of Nipah virus protects nonhuman primates A separate antibody, h5B3.1, targeting the fusion glycoprotein, also protected ferrets against both Nipah and the closely related Hendra virus.20PubMed Central. A Cross-Reactive Humanized Monoclonal Antibody Targeting Fusion Glycoprotein Function Protects Ferrets Against Lethal Nipah Virus and Hendra Virus Infection These are animal-model results, and the gap between primate studies and approved human therapy is wide, but they represent the most promising leads for post-exposure treatment.
Vaccines Are Getting Closer
Two vaccine candidates have reached early human trials. An mRNA vaccine developed by Moderna (mRNA-1215) uses a structure-based design similar to the platform used for COVID-19 vaccines. In a phase 1 trial in healthy adults, the vaccine was well tolerated with no serious adverse events. It generated strong antibody responses, including neutralizing antibodies within two weeks of the first dose. After a booster, those antibody levels remained elevated for at least a year.21Nature Medicine. A structure-based mRNA vaccine for Nipah virus in healthy adults: a phase 1 trial
A different approach comes from a recombinant protein vaccine originally designed against Hendra virus, a close relative of Nipah. Because the two viruses share structural similarities in their attachment glycoproteins, antibodies generated against one can neutralize the other. In a phase 1 trial, two doses of the vaccine given 28 days apart produced high neutralizing antibody levels against both the Bangladesh and Malaysia strains of Nipah. The induction of antibodies within one month suggests the vaccine could be useful not only for preventive vaccination of at-risk populations but also for reactive deployment during outbreaks.22The Lancet. Safety, tolerability, and immunogenicity of a recombinant subunit Hendra virus vaccine: a phase 1, randomised, observer-blind, placebo-controlled study
Neither vaccine is yet licensed for use. Nipah’s rarity, paradoxically, makes vaccine development harder: there are not enough cases in any given year to run a traditional efficacy trial. Animal-model data, immunobridging (comparing human antibody responses to those known to protect animals), and adaptive trial designs will likely be needed to bring a vaccine through regulatory approval.
Prevention on the Ground
Without an approved vaccine or drug, prevention in India relies on interrupting the chain from bat to human and from human to human. Practical measures include avoiding consumption of raw date palm sap or fruit that shows signs of bat feeding, such as tooth marks or partial consumption. In Bangladesh, simple bamboo skirts placed over the sap-collecting surface of date palms significantly reduced bat access.23PLoS ONE. A Randomized Controlled Trial of Interventions to Impede Date Palm Sap Contamination by Bats to Prevent Nipah Virus Transmission in Bangladesh While sap consumption is less of a documented factor in Kerala than in Bangladesh, the general principle of preventing bat contact with food and water sources applies.
Hospital infection control is equally critical. Kerala’s experience showed that strict isolation of suspected patients, proper use of personal protective equipment, and intensive contact tracing can stop an outbreak in its tracks. The 2019 response, where no secondary cases occurred from the index case, demonstrated that institutional preparedness built on previous failures can work.6PubMed Central. Nipah Virus Disease: Recent Perspective and One Health Approach
The Ecological Trap
One of the less obvious aspects of India’s Nipah problem is that human activity is making spillover more likely, not less. As forest cover has declined over centuries, Pteropus bats have shifted from roosting deep in forests to living in small colonies in human-settled areas, often near fruit orchards and crops. Most bat colonies now sit in zones of high human population density, where bats opportunistically feed on cultivated food resources rather than wild fruit.24PubMed Central. The Ecology of Nipah Virus in Bangladesh: A Nexus of Land-Use Change and Opportunistic Feeding Behavior in Bats This proximity creates exactly the conditions that promote viral spillover.
Public fear following outbreaks tends to make the situation worse. In Kerala, communities have responded to Nipah scares by cutting down trees where bats roost and using firecrackers to drive them away. While emotionally understandable, this is counterproductive: destroying bat habitats forces colonies to disperse, potentially carrying the virus to new areas. It also disrupts bats’ ecological roles, including seed dispersal, which matters for forest regeneration.25PLOS Global Public Health. Pandemic potential of the Nipah virus and public health strategies adopted during outbreaks: Lessons from Kerala, India Researchers have described this dynamic as a vicious cycle: outbreaks drive habitat destruction, habitat destruction increases the chance of future outbreaks.
Economic Fallout Beyond the Case Count
Nipah outbreaks in Kerala have produced economic ripples far out of proportion to the number of human cases. The fruit market in the state has collapsed during outbreak periods, with consumers refusing to buy not just wild fruit but commercially grown crops like areca nuts and cashew nuts out of fear of bat contamination. Fruit exports have been affected as well, even though no instance of the virus being transmitted through exported fruit has been documented.25PLOS Global Public Health. Pandemic potential of the Nipah virus and public health strategies adopted during outbreaks: Lessons from Kerala, India Containment measures such as localized lockdowns, even when geographically limited, disrupt daily economic activity in affected areas. For a disease that has killed dozens rather than thousands in India, the economic and psychological footprint is disproportionately large, driven by the virus’s high fatality rate and the understandable fear that accompanies it.
These downstream effects complicate public health messaging. Telling people to avoid bat-contaminated food is necessary, but if the message is received as “all fruit is dangerous,” the economic damage to farmers and exporters can be severe. Risk communication that is specific and actionable rather than broadly alarming remains one of the hardest challenges in Nipah preparedness.